NDA 218524 · Baxter Hlthcare Corp
Sodium Bicarbonate
Sodium Bicarbonate · Intravenous
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Aug 14, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
446
105 Phase 3, 28 recruiting
FAERS reports
23,575
20,176 serious, 4,325 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 14, 2026.
Sodium bicarbonate injection is an alkalinizing agent indicated: • to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. ( 1.1 ) • to alkalinize the urine in drug poisoning in adult and pediatric patients in cases in which urinary drug elimination is enhanced by urinary alkalinaztion. ( 1.2 ) Limitation of Use Do not use sodium bicarbonate injection in settings where rapid administration of sodium bicarbonate is required, such as cardiac arrest. In such situations use a more concentrated solution. 1.1 Treatment of Clinically Significant Metabolic Acidosis Sodium bicarbonate injection is indicated to raise plasma pH in adult and pediatric patients with clinically significant metabolic acidosis. 1.2 Urinary Alkalization in Drug Poisoning Sodium bicarbonate injection is indicated to alkalinize the urine in drug poisoning in adult and pediatric patients in cases in which urinary drug elimination is enhanced by urinary alkalinaztion. Limitation of Use Do not use sodium bicarbonate injection in settings where rapid administration of sodium bicarbonate is required, such as cardiac arrest. In such situations use a more concentrated solution.
Mechanism: Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SODIUM BICARBONATE · SODIUM BICARBONATE 150MEQ/1000ML (0.15MEQ/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bicarbonate" as an intervention, any sponsor and status, largest first.
International Vaccine InstituteAcademic, hospital or other
NCT00709410 · 51,151 participants · Start Jan 2009 · Primary completion Feb 2009
Drug: rBS-WC vaccine · For: Cholera; Diarrhea
Sites: Zanzibar, Tanzania
- Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in NigerPivotal-lookingCompleted
EpicentreAcademic, hospital or other
NCT02145000 · 6,586 participants · Start Jun 2014 · Primary completion Dec 2015
Drug: Rotavirus vaccine (BRV-PV); Placebo · For: Severe Rotavirus Gastroenteritis
Sites: Madarounfa, Niger
- Prevention of Serious Adverse Events Following AngiographyPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT01467466 · 5,177 participants · Start Oct 7, 2013 · Primary completion Sep 29, 2017
Drug: IV isotonic saline; IV isotonic bicarbonate and 2 more · For: Acute Renal Failure; Kidney Disease; Coronary Artery Disease
Sites: Tucson, Arizona; Little Rock, Arkansas; Palo Alto, California · 54 sites in all
- Safety and Efficacy of Sodium Bicarbonate Ringer InjectionPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04596956 · 5,000 participants (planned) · Start Oct 2020 · Primary completion Aug 2025
Drug: sodium bicarbonate Ringer injection; Lactated Ringer's solution · For: Ringer Bicarbonate; Elderly Abdominal Surgery; Safety and 1 more
- Effects of BRS and LRS on Postoperative Acute Kidney InjuryPivotal-lookingStatus unknown
Tongji HospitalAcademic, hospital or other
NCT04835038 · 3,400 participants (planned) · Start Jun 1, 2021 · Primary completion Jun 2023
Drug: Sodium Bicarbonate Ringer's Injection; Sodium Lactated Ringer's Injection · For: Acute Kidney Injury
Sites: Wuhan, China
- SAINT: Safe Induction of Labor TrialPivotal-lookingRecruiting
Oslo University HospitalAcademic, hospital or other
NCT05719467 · 3,000 participants (planned) · Start Jan 3, 2023 · Primary completion Jan 31, 2025
Drug: Buscopan 20 MG/ML Injectable Solution; Sodium bicarbonate and 2 more · For: Labor Complication; Induced; Birth; Pregnancy Related
Sites: Lørenskog, Norway; Oslo, Norway; Stavanger, Norway · 5 sites in all
- Sodium Bicarbonate in Cardiopulmonary ResuscitationPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT01377337 · 2,130 participants (planned) · Start Dec 2011 · Primary completion Dec 2013
Drug: sodium bicarbonate · For: Sudden Cardiac Arrest
Sites: Haifa, Israel; Tel Aviv, Israel
- Management of Myocardial Injury After Noncardiac Surgery TrialPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01661101 · 1,754 participants · Start Jan 2013 · Primary completion Mar 1, 2018
Drug: Dabigatran; Placebo (for Dabigatran) and 2 more · For: Myocardial Injury After Noncardiac Surgery (MINS)
Sites: Kansas City, Kansas; Buffalo, New York; Rochester, New York · 82 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- acute kidney injury1,735
- off label use1,699
- drug ineffective1,662
- diarrhoea1,477
- renal failure1,400
- nausea1,209
- anaemia1,137
- death1,076
- dyspnoea1,054
- pain996
- pneumonia993
- pyrexia985
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 108 |
| 2005 | 144 |
| 2006 | 172 |
| 2007 | 188 |
| 2008 | 230 |
| 2009 | 209 |
| 2010 | 364 |
| 2011 | 703 |
| 2012 | 624 |
| 2013 | 575 |
| 2014 | 831 |
| 2015 | 928 |
| 2016 | 1,330 |
| 2017 | 1,700 |
| 2018 | 1,457 |
| 2019 | 1,522 |
| 2020 | 1,615 |
| 2021 | 1,864 |
| 2022 | 1,940 |
| 2023 | 1,823 |
| 2024 | 1,908 |
| 2025 | 1,948 |
| 2026 | 1,390 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sodium Bicarbonate (Sodium Bicarbonate)
2024 spending
$567K
Beneficiaries
1,804
8,519 claims
Per beneficiary
$314
$0.25 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $517,768 |
| 2021 | $488,902 |
| 2022 | $610,163 |
| 2023 | $741,810 |
| 2024 | $567,270 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial.
Jung B, Jabaudon M, De Jong A, et al. · JAMA 2025 · Multicenter Study, Randomized Controlled Trial
- Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock.
Serpa Neto A, McNamara M, White K, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Sodium Bicarbonate for In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
Granfeldt A, Kirkegaard BL, Vallentin MF, et al. · JAMA 2026 · Equivalence Trial, Multicenter Study
- Sodium Bicarbonate for Acute Metabolic Acidosis in Critically Ill Adults: A Meta-Analysis of Randomized Clinical Trials.
Chen JJ, Lee TH, Chang CH, et al. · Crit Care Med 2026 · Meta-Analysis
- Sodium Bicarbonate Treatment and Clinical Outcomes in Chronic Kidney Disease with Metabolic Acidosis: A Meta-Analysis.
Yang TY, Lin HM, Wang HY, et al. · Clin J Am Soc Nephrol 2024 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Diphenhydramine, Sodium Bicarbonate, or Combination for Acute Peripheral Vertigo: A Randomized Clinical Trial.
Chi CY, Chen YC, Cheng MT, et al. · JAMA Netw Open 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Baxter Hlthcare Corp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.